Evaluation of some Methods for Preparing Gliclazide-β-Cyclodextrin Inclusion Complexes
Purpose: Gliclazide has been found to form inclusion complexes with β- cyclodextrin (β-CD) in solution and in solid state. The present study was undertaken to determine a suitable method for scaling up gliclazide-β-CD inclusion complex formation and to evaluate the effect of some parameters on the efficiency of complexation. Method: The solid inclusion complexes of gliclazide and β-cyclodextrin were prepared at a molar ratio of 1:1 and 1:2 by mixing, kneading, and coprecipitation methods both on small and large scales. The effect of parameters such as kneading time and temperature on complexation was also studied. Characterization was performed using infrared spectroscopy, X-ray diffractometry, and dissolution studies. In vitro release studies were carried out in phosphate buffer (pH 6.8). Result: All the methods of preparation of complexes were found to be useful in increasing the solubility of gliclazide except mixing method where the rise in solubility was not significant. Both kneading and co-precipitation methods in 1:2 molar ratios were found to be equally effective in improving the solubility of gliclazide. The formation of inclusion complexes was evident in these formulations as shown by IR and XRD studies. But when carried out on a large scale, co-precipitation method was found to be more tedious and time-consuming than kneading method. Moreover percent recovery of complexes in the kneading method was found to be 98.76% as compared to 92.05% in case of co-precipitation method. Conclusion: Drug content studies, IR spectroscopic studies, X-Ray diffractometry studies and in vitro dissolution study data indicated that inclusion complexes prepared by kneading method in 1:2 molar ratios were suitable for improving the solubility of gliclazide. The same formulation was prepared at large scale and optimum formulation conditions were established.
Keywords: Gliclazide, Inclusion complexes, β-cyclodextrin, Kneading
Tropical Journal of Pharmaceutical Research Vol. 6 (4) 2007: pp. 833-840
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.